Parkman Healthcare Partners

Gregory Martinez is the Managing Member and Chief Investment Officer. The partnership structure includes five named partners — Martinez, Michael Elgort, Jeremy Chase, Logan Unland, and Matthew Ostrup — but the firm’s website does not specify whether decisions are made by Martinez alone or by an investment committee that includes the other partners.

Parkman describes its process as thematic growth investing combined with risk management and protection. The firm targets value inflection points as standards of care evolve, applying a fundamental research process across biotech, pharma, medical devices, diagnostics, life science research, and services. No portfolio company names are publicly disclosed.

No. The firm does not publicly disclose assets under management, specific fund vehicles, or discrete deployment figures. Employee ownership is stated, but there is no mention of closed-end fund structures, open-ended vehicles, or separate managed accounts on the public website.

The firm states it seeks out innovations globally, though its listed office footprint is entirely domestic US. Without disclosed portfolio companies, it is impossible to confirm whether deployed capital extends to ex-US healthcare companies or remains concentrated in US-based small- and mid-cap names.